SI2594265T1 - CA-IX specifični inhibitorji - Google Patents

CA-IX specifični inhibitorji

Info

Publication number
SI2594265T1
SI2594265T1 SI200332462T SI200332462T SI2594265T1 SI 2594265 T1 SI2594265 T1 SI 2594265T1 SI 200332462 T SI200332462 T SI 200332462T SI 200332462 T SI200332462 T SI 200332462T SI 2594265 T1 SI2594265 T1 SI 2594265T1
Authority
SI
Slovenia
Prior art keywords
specific inhibitors
inhibitors
specific
Prior art date
Application number
SI200332462T
Other languages
English (en)
Inventor
Claudiu Supuran
Andrea Scozzafava
Silvia Pastorekova
Jaromir Pastorek
Original Assignee
Institute Of Virology Slovak Academy Of Sciences
Claudiu Supuran
Andrea Scozzafava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Virology Slovak Academy Of Sciences, Claudiu Supuran, Andrea Scozzafava filed Critical Institute Of Virology Slovak Academy Of Sciences
Publication of SI2594265T1 publication Critical patent/SI2594265T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200332462T 2002-11-26 2003-11-26 CA-IX specifični inhibitorji SI2594265T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42908902P 2002-11-26 2002-11-26
US48947303P 2003-07-22 2003-07-22
US51510403P 2003-10-28 2003-10-28
EP12179990.2A EP2594265B1 (en) 2002-11-26 2003-11-26 Ca ix-specific inhibitors

Publications (1)

Publication Number Publication Date
SI2594265T1 true SI2594265T1 (sl) 2016-03-31

Family

ID=32397981

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332462T SI2594265T1 (sl) 2002-11-26 2003-11-26 CA-IX specifični inhibitorji

Country Status (9)

Country Link
US (2) US7550424B2 (sl)
EP (2) EP2594265B1 (sl)
JP (2) JP4713341B2 (sl)
AU (1) AU2003295950B2 (sl)
CA (2) CA2506983C (sl)
DK (1) DK2594265T3 (sl)
HU (1) HUE028349T2 (sl)
SI (1) SI2594265T1 (sl)
WO (1) WO2004048544A2 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100135980A1 (en) * 2000-10-16 2010-06-03 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
HUE028349T2 (en) * 2002-11-26 2016-12-28 Inst Virology CAIX-specific inhibitors
WO2006137092A1 (en) * 2005-06-23 2006-12-28 Supuran Claudiu T Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as theapeutic and diagnostic agents
LT5504B (lt) 2006-08-02 2008-06-25 Biotechnologijos Institutas Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti
CA2683434A1 (en) * 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
WO2009089383A2 (en) 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
EP2373622A2 (en) 2008-12-05 2011-10-12 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
US20100317533A1 (en) * 2009-06-05 2010-12-16 British Columbia Cancer Agency Branch Biomarkers of cancer metastasis
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
EP2590938B1 (en) * 2010-07-09 2017-06-07 Welichem Biotech Inc. Novel sulfonamide compounds for inhibition of metastatic tumor growth
CA2856812A1 (en) * 2010-11-28 2012-05-31 Metasignal Therapeutics Inc. Carbonic anhydrase inhibitors with antimetastatic activity
NL1038473C2 (en) 2010-12-24 2012-06-27 Centre Nat Rech Scient Cancer targeting using carbonic anhydrase isoform ix inhibitors.
WO2012175654A1 (en) 2011-06-23 2012-12-27 Facultes Universitaires Notre-Dame De La Paix Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders
US10195174B2 (en) 2011-10-24 2019-02-05 Signalchem Lifesciences Corporation Carbonic anhydrase IX-related markers and use thereof
CZ2011676A3 (cs) 2011-10-24 2013-05-02 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Inhibitory karbonické anhydrasy, zpusob jejich prípravy
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
EP2740491A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy
ES2648096T3 (es) 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes
ITRM20130138A1 (it) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche Assemblato comprendente un assorbitore della luce nel vicino infrarosso legato covalentemente ad un inibitore dell'anidrasi carbonica
US9958018B2 (en) 2013-04-30 2018-05-01 Aisin Aw Co., Ltd. Transmission device
WO2015025283A2 (en) 2013-08-20 2015-02-26 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Dual action carbonic anhydrase inhibitors
WO2015101609A1 (en) * 2013-12-31 2015-07-09 Stichting Katholieke Universiteit Method for treating renal disorders
CA2938574C (en) * 2014-02-03 2019-04-02 Eidgenoessische Technische Hochschule Zurich Low molecular weight drug conjugates for binding to carbonic anhydrase ix
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE167473T1 (de) * 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
WO2000024913A2 (en) 1998-10-23 2000-05-04 Bayer Corporation Mn gene and protein
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6027887A (en) * 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
WO1995034650A2 (en) 1994-06-15 1995-12-21 Ciba Corning Diagnostics Corp. Mn gene and protein
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6034099A (en) 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
HUE028349T2 (en) * 2002-11-26 2016-12-28 Inst Virology CAIX-specific inhibitors

Also Published As

Publication number Publication date
HUE028349T2 (en) 2016-12-28
US20080095707A1 (en) 2008-04-24
CA2691447A1 (en) 2004-06-10
US7550424B2 (en) 2009-06-23
CA2506983A1 (en) 2004-06-10
EP1569633A2 (en) 2005-09-07
CA2506983C (en) 2010-03-30
EP1569633A4 (en) 2008-03-05
DK2594265T3 (en) 2015-12-21
AU2003295950B2 (en) 2007-06-28
EP2594265A3 (en) 2013-09-04
EP2594265A1 (en) 2013-05-22
US7829065B2 (en) 2010-11-09
AU2003295950A1 (en) 2004-06-18
JP2011075570A (ja) 2011-04-14
JP2006509844A (ja) 2006-03-23
WO2004048544A2 (en) 2004-06-10
US20040146955A1 (en) 2004-07-29
WO2004048544A3 (en) 2004-09-16
EP2594265B1 (en) 2015-10-28
JP4713341B2 (ja) 2011-06-29

Similar Documents

Publication Publication Date Title
SI2594265T1 (sl) CA-IX specifični inhibitorji
EG25482A (en) Inhibitors
PL373146A1 (en) Pyridazinone-derivatives as pde4 inhibitors
EP1496910A4 (en) KINASE INHIBITORS
AU2003300832A8 (en) Nf-kappab inhibitors
EP1474093A4 (en) INHIBITORS OF GRANZYME B
EP1499336A4 (en) PROTEASE INHIBITORS
EP1558609A4 (en) KINASE INHIBITORS
EP1532133A4 (en) NF-: B INHIBITORS
GB0219961D0 (en) Oxytocin inhibitors
EP1569907A4 (en) NICOTINAMIDE-BASED KINASE HEMMER
AU2003299901A8 (en) Thrombin inhibitors
EP1570847A4 (en) PHOSPHODIESTERASE 10A HEMMER
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
EP1531857A4 (en) Metalloproteinase inhibitors
AU2003269984A8 (en) Protease inhibitors
AU2003224941A8 (en) Nf-kappab inhibitors
AU2003242559A8 (en) Alkylaminosiloxanes as corrosion inhibitors
AU2003263738A8 (en) Protease inhibitors
AU2003233642A8 (en) Protease inhibitors
AU2003304496A8 (en) Protease inhibitors
AU2003227952A8 (en) Metalloproteinase inhibitors
AU2003269878A8 (en) Protease inhibitors
AU2003265240A8 (en) Protease inhibitors
GB0226149D0 (en) Inhibitors